Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hybrigenics has received EUR 800,000 as the second and last payment of a EUR1.4m refundable grant contract originally signed with Oseo Innovation, in 2008.
Subscribe to our email newsletter
Hybrigenics said that the transaction follows the successful completion of Phase IIa clinical tolerance study of oral inecalcitol in hormone-refractory prostate cancer patients.
The first payment of EUR600,000 was received at the signature of the contract.
Hybrigenics CFO Guillaume Floch said that this is a significant grant for Hybrigenics and shows Oseo’s confidence in their product and in the ability to successfully complete clinical trials.
"The total EUR1.4m will be reimbursed between 2012 and 2015 and this final payment will help fund further clinical development of inecalcitol," Floch said.